Literature DB >> 7850979

Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a)

W Terres1, E Tatsis, B Pfalzer, F U Beil, U Beisiegel, C W Hamm.   

Abstract

BACKGROUND: The mechanisms underlying rapid angiographic progression of coronary artery disease are still unknown. Intravascular thrombosis with or without plaque rupture may be involved. METHODS AND
RESULTS: In a prospective study in 79 patients with coronary artery disease and at least one coronary diameter stenosis > or = 50%, possible risk factors for rapid progression were investigated. Quantitative coronary angiography was performed twice at a mean time interval of 66 +/- 25 days. Rapid progression of coronary disease defined as (1) an increase > 10% in stenosis severity in at least one stenosis > or = 50%, (2) occurrence of a new stenosis > or = 50%, or (3) occlusion of a formerly patent vessel was found in 21 patients (27%). Between patients with rapid progression and those without, there were no significant differences in sex distribution, age, smoking history, frequency of hypertension or diabetes mellitus, and serum LDL cholesterol, HDL cholesterol, and apolipoprotein B concentrations. In contrast, serum lipoprotein(a) [Lp(a)] concentrations > or = 25 mg/dL were found in 14 of 21 patients (67%) with rapid progression of coronary artery disease but in only 19 of 58 (33%) in the group without progression (P = .007). The respective median Lp(a) concentrations were 66 mg/dL (range, 2 to 139) and 13 mg/dL (range, 2 to 211; P = .01).
CONCLUSIONS: Lp(a) appears to be a risk factor for the rapid angiographic progression of coronary artery disease. The pathophysiological link between Lp(a) and rapid progression may be an interference with thrombolysis through the partial structural homology of Lp(a) with plasminogen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850979     DOI: 10.1161/01.cir.91.4.948

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

2.  Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.

Authors:  Zhe Feng; Hua-Long Li; Wei-Jie Bei; Xiao-Sheng Guo; Kun Wang; Shi-Xin Yi; De-Mou Luo; Xi-da Li; Shi-Qun Chen; Peng Ran; Peng-Yuan Chen; Sheikh Mohammed Shariful Islam; Ji-Yan Chen; Yong Liu; Ying-Ling Zhou
Journal:  Clin Cardiol       Date:  2017-04-26       Impact factor: 2.882

3.  Hypercholesterolemia and Dyslipidemia: Issues for the Clinician.

Authors:  H. Robert Superko; Nicolas A. Chronos
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-02

4.  Hereditary dyslipidemias and combined risk factors in children with a family history of premature coronary artery disease.

Authors:  T Sveger; C E Flodmark; K Nordborg; P Nilsson-Ehle; N Borgfors
Journal:  Arch Dis Child       Date:  2000-04       Impact factor: 3.791

5.  Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease.

Authors:  S M Jones; C P Harris; J Lloyd; C A Stirling; J P Reckless; N J McHugh
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

6.  Relation of Plasma Lipoprotein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Severe Coronary Stenoses in Apparently Healthy African-Americans With a Family History of Early-Onset Coronary Artery Disease.

Authors:  Brian G Kral; Rita R Kalyani; Lisa R Yanek; Dhananjay Vaidya; Elliot K Fishman; Diane M Becker; Lewis C Becker
Journal:  Am J Cardiol       Date:  2016-07-05       Impact factor: 2.778

7.  A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.

Authors:  Jane Hoover-Plow; Erika Hart; Yanqing Gong; Aleksey Shchurin; Tracey Schneeman
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07

8.  Oxidized lipoprotein(a) increases endothelial cell monolayer permeability via ROS generation.

Authors:  Deng-heng Wei; Xiao-lei Zhang; Ren Wang; Jun-fa Zeng; Kai Zhang; Jian Yang; Shuang Li; Xiao-long Lin; Zhi-sheng Jiang; Gui-xue Wang; Zuo Wang
Journal:  Lipids       Date:  2013-05-15       Impact factor: 1.880

9.  Association of Elevated Serum Lipoprotein(a), Inflammation, Oxidative Stress and Chronic Kidney Disease with Hypertension in Non-diabetes Hypertensive Patients.

Authors:  Surapon Tangvarasittichai; Patcharin Pingmuanglaew; Orathai Tangvarasittichai
Journal:  Indian J Clin Biochem       Date:  2016-01-29

10.  Gemfibrozil treatment in patients with elevated lipoprotein a: a pilot study.

Authors:  A G Fereshetian; M Davidson; H Haber; D M Black
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.